A new variant of human mpox has claimed the lives of approximately 5% of people with reported infections in the Democratic Republic of the Congo since 2023, many of them children. Since then, it has ...
Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...
The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi â„¢ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...
BeWell, New Mexico’s health insurance marketplace, works to help people who don’t qualify for Medicaid or Medicare find ...
Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with ...
Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart ...
Through the new three-year initiative, nine community-based organizations ... where an initial group of project partners will come together for will receive information about the program and walk away ...
Fewer and fewer twins and triplets are being born through IVF in Australia, bringing IVF and overall Australian multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback